Association of FDG PET/CT and immune profiling with pathologic complete response after neoadjuvant immunotherapy in stage II–III non-small cell lung cancer

초록

Background: Neoadjuvant immunotherapy has emerged as a transformative approach for resectable non-small cell lung cancer (NSCLC). Pathologic complete response (pCR) after neoadjuvant therapy serves as a robust surrogate marker for early treatment efficacy and long-term outcomes. However, reliable noninvasive predictors of pCR before surgery remain an unmet clinical need. This study investigated the association between fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) parameters and tumor-infiltrating immune cell subsets in pre-treatment biopsies with pCR in patients with stage II–III NSCLC treated with immune checkpoint inhibitor (ICI)-based neoadjuvant therapy. Methods: We retrospectively analyzed 13 patients with stage II–III NSCLC who underwent ICI-based neoadjuvant therapy and baseline FDG PET/CT. pCR was assessed in resected surgical specimens. PET/CT parameters, including tumor-to-liver ratio (TLR) and maximum standardized uptake value (SUVmax), were evaluated before and after neoadjuvant treatment. Multiplex immunofluorescence (mIF) was performed on pre-treatment tumor biopsies to quantify tumor-infiltrating immune cell subsets and functional immune markers. Results: Eight patients (62%) achieved pCR. Compared with the non-pCR group, patients with pCR showed significantly lower post-treatment TLR (median 1.51 vs. 2.14, P=0.004) and a greater relative reduction in TLR (median 0.82 vs. 0.58, P=0.004). Pre-treatment biopsies from patients with pCR demonstrated higher infiltration of CD4^+ T cells (P=0.04) and increased TIGIT expression on both CD8^+ and CD4^+ T cells. Pre-treatment TLR positively correlated with CD68^+ macrophages and Ki67^+ CD8^+ T cells, while changes in TLR were significantly associated with TIGIT^+ tumor-infiltrating T cells. During follow-up, recurrence occurred in only one patient in the non-pCR group. Conclusions: Dynamic changes in PET/CT-derived TLR and immune biomarkers from pre-treatment biopsies were associated with pCR following neoadjuvant immunotherapy in stage II–III NSCLC. These findings support the complementary role of metabolic imaging and immune profiling in improving patient selection and perioperative decision-making. © AME Publishing Company. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

키워드